Free Trial

UBS Group's Rating of Biostage on 10/13/2025

On October 13, 2025, UBS Group updated its outlook on Biostage (OTCMKTS:BSTG) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from UBS Group AG

DateCompanyAction
10/13/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
Set Price Target
10/13/2025
Aveanna Healthcare Holdings Inc. stock logo
AVAH
Aveanna Healthcare
Boost Price Target
10/13/2025
BrightSpring Health Services, Inc. stock logo
BTSG
BrightSpring Health Services
Boost Price Target
10/13/2025
Dycom Industries, Inc. stock logo
DY
Dycom Industries
Boost Price Target
10/13/2025
Service Corporation International stock logo
SCI
Service Corporation International
Boost Price Target
10/13/2025
Exxon Mobil Corporation stock logo
XOM
Exxon Mobil
Boost Price Target
More Ratings From UBS Group AG